
Genetic testing for homologous recombination repair (HRR) mutations is underutilized in patients with metastatic castration-resistant prostate cancer (mCRPC) in the United States, despite its potential prognostic and predictive value for targeted therapies.


coremsg

Most men with mCRPC in the United States do not receive recommended genetic testing for relevant mutations, suggesting efforts are needed to address barriers to testing.

Genetic Testing Low in Castration-Resistant Prostate Cancer

underutilization-of-genetic-testing-for-homologous-recombination-repair-mutations-in-metastatic-castration-resistant-prostate-cancer-patients-in-the-united-states


Underutilization of Genetic Testing for Homologous Recombination Repair Mutations in Metastatic Castration-Resistant Prostate Cancer Patients in the United States
